These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36573662)

  • 1. Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome.
    Xie T; Wills AM; Liao C; Dale ML; Ramsden DB; Padmanaban M; Abou Chaar W; Pantelyat A; Golbe LI
    Mov Disord; 2023 Feb; 38(2):304-312. PubMed ID: 36573662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy.
    Xie T; Yuen CA; Kang W; Padmanaban M; Hain TC; Nichols J
    Front Neurol; 2021; 12():736784. PubMed ID: 34650511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
    Litvan I; Mangone CA; McKee A; Verny M; Parsa A; Jellinger K; D'Olhaberriague L; Chaudhuri KR; Pearce RK
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy.
    Abate F; Russo M; Ricciardi C; Tepedino MF; Romano M; Erro R; Pellecchia MT; Amboni M; Barone P; Picillo M
    Parkinsonism Relat Disord; 2023 Apr; 109():105345. PubMed ID: 36868037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy.
    Golbe LI; Ohman-Strickland P; Beisser EB; Elghoul FT
    Mov Disord Clin Pract; 2020 Aug; 7(6):664-671. PubMed ID: 32775512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.
    Shoeibi A; Litvan I; Tolosa E; Ser TD; Lee E;
    Parkinsonism Relat Disord; 2019 Sep; 66():87-93. PubMed ID: 31307919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysphagia in Progressive Supranuclear Palsy.
    Clark HM; Stierwalt JAG; Tosakulwong N; Botha H; Ali F; Whitwell JL; Josephs KA
    Dysphagia; 2020 Aug; 35(4):667-676. PubMed ID: 31676923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
    Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L
    Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.
    Bang J; Lobach IV; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Gold M; Morimoto BH; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():41-48. PubMed ID: 27172829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
    Hewer S; Varley S; Boxer AL; Paul E; Williams DR;
    Mov Disord; 2016 Oct; 31(10):1574-1577. PubMed ID: 27324431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.
    Sakae N; Josephs KA; Litvan I; Murray ME; Duara R; Uitti RJ; Wszolek ZK; Graff-Radford NR; Dickson DW
    Mov Disord; 2019 Nov; 34(11):1655-1662. PubMed ID: 31433871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments.
    Wills AM; Pantelyat A; Espay A; Chan J; Litvan I; Xie T; Dale ML; Gunzler SA; Tartaglia MC; Fox SH; Rodriguez-Porcel F; Sharma M; Lang AE; Boxer AL; ; Golbe LI
    Mov Disord; 2022 Jun; 37(6):1265-1271. PubMed ID: 35363932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy.
    Pagonabarraga J; Horta-Barba A; Busteed L; Bejr-Kasem H; Illán-Gala I; Aracil-Bolaños I; Marín-Lahoz J; Pascual-Sedano B; Pérez J; Campolongo A; Izquierdo C; Martinez-Horta S; Sampedro F; Kulisevsky J
    Parkinsonism Relat Disord; 2021 Apr; 85():63-68. PubMed ID: 33744691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy.
    Goetz CG; Leurgans S; Lang AE; Litvan I
    Neurology; 2003 Mar; 60(6):917-22. PubMed ID: 12654953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy.
    Oliveira MCB; Ling H; Lees AJ; Holton JL; De Pablo-Fernandez E; Warner TT
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):555-561. PubMed ID: 30598430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.
    Sotirakis C; Conway N; Su Z; Villarroel M; Tarassenko L; FitzGerald JJ; Antoniades CA
    Mov Disord; 2022 Nov; 37(11):2263-2271. PubMed ID: 36054142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eye movements and association with regional brain atrophy in clinical subtypes of progressive supranuclear palsy.
    Choi JH; Kim H; Shin JH; Lee JY; Kim HJ; Kim JM; Jeon B
    J Neurol; 2021 Mar; 268(3):967-977. PubMed ID: 32959131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.
    Glasmacher SA; Leigh PN; Saha RA
    J Neurol Neurosurg Psychiatry; 2017 May; 88(5):402-411. PubMed ID: 28250027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical rating scale for progressive supranuclear palsy.
    Golbe LI; Ohman-Strickland PA
    Brain; 2007 Jun; 130(Pt 6):1552-65. PubMed ID: 17405767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midbrain/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy.
    Cui SS; Ling HW; Du JJ; Lin YQ; Pan J; Zhou HY; Wang G; Wang Y; Xiao Q; Liu J; Tan YY; Chen SD
    BMC Neurol; 2020 Mar; 20(1):114. PubMed ID: 32228519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.